What Jacobio Pharmaceuticals does

Jacobio Pharmaceuticals (加科思药业) is a Beijing-headquartered, Hong Kong-listed (1167.HK) biopharmaceutical company founded in 2015 by Dr. Wang Yixiang, focused on developing first-in-class small molecule and antibody-drug conjugate therapies targeting traditionally undruggable oncogenic pathways. Its proprietary technology platforms — the Induced Allosteric Drug Discovery Platform and the iADC Platform — underpin a pipeline of 10+ programs spanning six tumor signaling pathways (P53, RAS, RB, MYC, Immune Checkpoint, Tumor Metabolism). Core clinical assets include KRAS G12C inhibitor glecirasib (first commercial product approved in China in 2025 and NRDL-listed), SHP2 inhibitors JAB-3068/JAB-3312 (licensed to AbbVie), pan-KRAS inhibitor JAB-23E73 (licensed to AstraZeneca in December 2025), plus CD73 antibody JAB-BX102, Aurora A inhibitor JAB-2485, BET inhibitor JAB-8263, and an iADC pipeline (JAB-BX600, JAB-BX467). The company holds 300+ global patent applications and operates 100+ clinical centers across China and the US, with offices in Beijing, Shanghai, and Boston (Burlington, MA).

The company's go-to-market model is a dual licensing/commercialization approach. For pipeline assets, Jacobio out-licenses global development and commercialization rights to multinational pharmaceutical partners (e.g., AstraZeneca for JAB-23E73 at up to $2.015B total deal value including $100M upfront; AbbVie for SHP2 inhibitors at up to $855M including $45M upfront), receiving upfront payments, development/regulatory/commercial milestones, and tiered royalties on ex-China net sales. The company retains exclusive China rights and engages in co-development and profit-sharing within China. For its approved product glecirasib, Jacobio commercializes directly through Chinese hospital and pharmacy distribution networks with NRDL reimbursement coverage; this generated RMB 8.55 million in revenue from June to December 2025. The company's revenue model effectively combines license/milestone income (the dominant near-term revenue stream) with nascent direct product sales, supplemented by a strategic investment in Hebecell for iPSC-NK cell therapy development. Management guides to exceeding RMB 2.0 billion in cash and achieving profitability in 2026, supported by the December 2025 AstraZeneca upfront payment and ongoing milestone catalysts.

Name

Jacobio Pharmaceuticals

Legal name

Beijing Jacobio New Drug R&D Co., Ltd.

Website

https://en.jacobiopharma.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Jacobio Pharmaceuticals is a Beijing-based, Hong Kong-listed (1167.HK) biopharmaceutical company developing first-in-class oncology drugs targeting traditionally undruggable pathways (KRAS, SHP2, MYC, P53) using its proprietary allosteric drug discovery and iADC platforms, serving global pharmaceutical partners and Chinese cancer patients.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Oncology drug development
• Allosteric inhibitor discovery
• KRAS targeted therapy
• Antibody-drug conjugates
• Biopharmaceutical licensing

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Drug Licensing and Milestone Payments: Jacobio out-licenses proprietary clinical-stage assets to global pharma companies (e.g., AstraZeneca for JAB-23E73 at up to $2.015B including $100M upfront; AbbVie for SHP2 inhibitors at up to $855M). Revenue consists of upfront payments, development/regulatory/commercial milestone payments, and tiered royalties on net sales outside China. Co-development and profit-sharing in China.
2. Product Sales (China): Revenue from commercialized product glecirasib sold in China after approval and National Reimbursement Drug List inclusion in 2025. Generated RMB 8.55 million in revenue from June to December 2025.

Pricing tiers

Distribution channels2 records

Marketing channels3 records

Core offering

Jacobio Pharmaceuticals is a clinical- and commercial-stage biopharmaceutical company that develops first-in-class small molecule drugs and antibody-drug conjugates (ADCs) targeting historically undruggable oncogenic pathways in cancer. Its portfolio spans six tumor signaling pathways (P53, RAS, RB, MYC, I/O, and tumor metabolism) and is anchored by proprietary allosteric inhibitor and iADC technology platforms. The company monetizes through global out-licensing deals (with upfront fees, milestones, and royalties) and direct sales of approved products in China, with glecirasib (KRAS G12C inhibitor) being its first commercial product.

Product overview

Jacobio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing first-in-class drugs targeting validated yet traditionally undruggable oncogenic pathways. The company's portfolio centers on six key tumor signaling pathways (RAS, MYC, RB, I/O, tumor metabolism, and P53) and includes both small molecule inhibitors and antibody-drug conjugates. Core clinical-stage products include glecirasib (first approved commercial product), SHP2 inhibitors (JAB-3068/JAB-3312) partnered with AbbVie, Pan-KRAS inhibitor JAB-23E73 partnered with AstraZeneca, and multiple other candidates including KRAS G12C, CD73, BET, and Aurora A inhibitors. The company operates proprietary induced allosteric drug discovery and iADC platforms, with manufacturing and R&D facilities in Beijing, Shanghai, and Boston.

Differentiator

Problem solved

Functional benefit

Products and services

• Glecirasib (KRAS G12C inhibitor) KRAS G12C inhibitor approved in China for cancer treatment, targeting KRAS G12C-mutated non-small cell lung cancer and other solid tumors. Jacobio's first commercial product.
• JAB-23E73 (Pan-KRAS Inhibitor) Pan-KRAS inhibitor in Phase I trials targeting multiple KRAS mutation subtypes (G12C, G12D, G12V, etc.) present in approximately 23% of all cancer patients, including pancreatic, colorectal, and lung cancers.
• SHP2 Inhibitors (JAB-3068, JAB-3312) Globally first-in-class SHP2 allosteric inhibitors. JAB-3312 is in Phase II efficacy exploration in combination with PD-1 antibodies and MEK inhibitors; received FDA Orphan Drug Designation for esophageal cancer.
• JAB-21822 (KRAS G12C Inhibitor) High-selectivity KRAS G12C allosteric inhibitor for solid tumors including NSCLC and colorectal cancer, developed as monotherapy and in combination with SHP2 inhibitors, PD-1 antibodies, and cetuximab.
• JAB-BX102 (CD73 Antibody) CD73 monoclonal antibody targeting the tumor adenosine pathway for solid tumors; first macro-molecule in Jacobio's pipeline.
• JAB-8263 (BET Inhibitor) BET inhibitor for cancer treatment, with myelofibrosis as a key indication; clinical trials ongoing in China and the US.
• JAB-2485 (Aurora A Inhibitor) High-selectivity Aurora A inhibitor for advanced solid tumors; third Aurora A inhibitor to enter clinical trials globally.
• JAB-BX600 and JAB-BX467 (ADC Programs) Antibody-drug conjugate (ADC) pipeline programs in IND preparation stage for cancer treatment, developed using Jacobio's iADC platform.
• Induced Allosteric Drug Discovery Platform Proprietary drug discovery platform enabling the development of allosteric inhibitors targeting protein phosphatases (e.g., SHP2), KRAS mutations (G12C, G12D, G12V), and transcription factors traditionally considered undruggable.
• iADC Platform Proprietary immunotherapy antibody-drug conjugate (ADC) platform for developing next-generation ADC cancer therapies, including JAB-BX600 and JAB-BX467.

Quantifiable outcome

• SHP2 inhibitor SHP2+PD-1 combination achieved $20M milestone payment trigger upon first patient dosing
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship, core and supporting.

• AstraZenecaflagshipStrategic or Co-development Partner · 21 December 2025AstraZeneca acquired global exclusive licensing rights for Jacobio's pan-KRAS inhibitor JAB-23E73 in a deal worth up to $2.015 billion ($100M upfront + up to $1.915B in milestones plus royalties). AstraZeneca handles development and commercialization outside China; both companies co-develop and share profits within China. JAB-23E73 targets multiple KRAS mutations present in ~23% of all cancer patients.
• HebecellcoreStrategic or Co-development Partner · 31 August 2021Strategic investment in US biotech company Hebecell for global co-development of iPSC-NK (induced pluripotent stem cell natural killer) cell therapies. Hebecell uses proprietary 3D suspension feeder-free culture technology to produce off-the-shelf NK cell therapies. Jacobio CEO Dr. Wang Yinxiang also serves as Hebecell Chairman.
• AI Drug Discovery Partners (XtalPi,晶泰科技)supportingTechnology or Integration · 31 August 2021Partnerships with AI drug discovery companies including XtalPi (晶泰科技) to accelerate early-stage drug discovery for difficult-to-drug targets using AI and quantum physics-based algorithms.
• AbbVieflagshipStrategic or Co-development Partner · 1 June 2020Global strategic collaboration with AbbVie for co-development and co-commercialization of SHP2 inhibitors (JAB-3068 and JAB-3312). Jacobio received $45M upfront plus research reimbursement, with up to $810M in milestone payments and tiered royalties. Jacobio retains exclusive development and commercialization rights in China, with profit sharing in China.
• WuXi AppTec / WuXi Biologics / Pharmaron / Asymchem / Viva Bio / HitgensupportingOthersNetwork of contract research organizations and contract development and manufacturing organizations for conducting preclinical studies, clinical trials, and manufacturing services.

Scale indicators9 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Mirati Therapeutics: Mirati Therapeutics developed adagrasib (Krazati), a KRAS G12C inhibitor approved for NSCLC, and was acquired by Bristol Myers Squibb for $4.8B in 2024. Most direct competitor to Jacobio's KRAS G12C inhibitor JAB-21822 and a benchmark for valuation in the KRAS space.
• Erasca: Erasca is a clinical-stage precision oncology company focused exclusively on developing therapies for patients with RAS/MAPK pathway-driven cancers. Comparable to Jacobio in targeting RAS-pathway mutations including KRAS, with similar business model of building pipeline around a core pathway focus.
• CStone Pharmaceuticals: CStone Pharmaceuticals is a clinical-stage Chinese biopharmaceutical company developing immuno-oncology and precision medicines with global out-licensing deals (e.g., with Bayer, EQRx). Comparable to Jacobio as a peer Chinese clinical-stage oncology company with similar partnership-driven business model and HK/US listings.
• GenFleet Therapeutics: GenFleet is a Chinese clinical-stage biotechnology company developing oncology therapies including KRAS inhibitors and other targeted agents. Comparable to Jacobio as a domestic Chinese competitor pursuing similar KRAS and oncology targets with out-licensing ambitions.
• Relay Therapeutics: Relay Therapeutics is a precision oncology company using computational approaches to develop allosteric inhibitors against targets including PI3Kα and KRAS. Comparable to Jacobio in emphasizing allosteric mechanisms for previously undruggable oncology targets with clinical-stage assets.
• Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing RAS-targeted therapies including pan-RAS and pan-KRAS inhibitors (e.g., RMC-6236). Highly comparable to Jacobio as both target KRAS mutations across multiple subtypes with novel mechanisms, competing directly in the pan-KRAS space that Jacobio licensed to AstraZeneca.
• Hutchmed: Hutchmed is a Hong Kong-listed clinical-stage biopharmaceutical company developing innovative oncology and immunology therapies in China and globally. Directly comparable to Jacobio as a Chinese-headquartered, HKEX-listed clinical-stage oncology company with both internal pipeline and global partnership model.

Broad incumbents

• Amgen: Amgen developed and commercializes Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor. While a much larger incumbent, Amgen represents the established competition in Jacobio's core KRAS G12C space and validates the commercial potential of the target category.
• BeiGene: BeiGene is a global oncology-focused biopharmaceutical company with multiple approved products including Brukinsa and tislelizumab, with significant China and global commercial operations. Comparable to Jacobio as a Chinese-headquartered oncology company with both domestic commercialization and global development partnerships.
• Innovent Biologics: Innovent Biologics is a leading Chinese biopharmaceutical company with multiple approved oncology biologics including PD-1 antibody Tyvyt. Larger and broader than Jacobio with established commercial infrastructure and partnered assets (e.g., with Eli Lilly), serving as a benchmark Chinese biopharma comparable to Jacobio's growth trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jacobio Pharmaceuticals